JAK Inhibitor Clinical Trials
4 recruitingDrug
Phase 23
Showing 1–4 of 4 trials
Recruiting
Phase 2
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Myelodysplastic/Myeloproliferative NeoplasmPrimary MyelofibrosisSecondary Myelofibrosis
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07228624
Recruiting
Phase 2
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Primary MyelofibrosisSecondary Myelofibrosis
Fred Hutchinson Cancer Center20 enrolled1 locationNCT04370301
Recruiting
Phase 2
JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial
Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Shixiu Wu35 enrolled1 locationNCT06715982
Recruiting
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
Ulcerative Colitis (Disorder)
Humanitas Clinical and Research Center450 enrolled1 locationNCT06691061